107 related articles for article (PubMed ID: 29959021)
21. Type specific and genotype cross reactive B epitopes of the L1 protein of HPV16 defined by a panel of monoclonal antibodies.
Kulski JK; Sadleir JW; Kelsall SR; Cicchini MS; Shellam G; Peng SW; Qi YM; Galloway DA; Zhou J; Frazer IH
Virology; 1998 Apr; 243(2):275-82. PubMed ID: 9568027
[TBL] [Abstract][Full Text] [Related]
22. Expression of HPV6b L1/EBV LMP2 multiepitope and immunogenicity in mice.
Zhu S; Xue X; Liu J; Lu L; Zhao P; Wang J; Li W; Zhang L
Acta Biochim Biophys Sin (Shanghai); 2010 Aug; 42(8):515-21. PubMed ID: 20705592
[TBL] [Abstract][Full Text] [Related]
23. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6.
Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
J Virol; 1999 Jul; 73(7):6188-90. PubMed ID: 10364381
[TBL] [Abstract][Full Text] [Related]
24. Protective immunity against Chlamydia trachomatis genital infection induced by a vaccine based on the major outer membrane multi-epitope human papillomavirus major capsid protein L1.
Xu W; Liu J; Gong W; Chen J; Zhu S; Zhang L
Vaccine; 2011 Mar; 29(15):2672-8. PubMed ID: 21324344
[TBL] [Abstract][Full Text] [Related]
25. HPV16 L1 capsid protein expressed from viable adenovirus recombinants elicits neutralizing antibody in mice.
Berg M; Gambhira R; Siracusa M; Hoiczyk E; Roden R; Ketner G
Vaccine; 2007 Apr; 25(17):3501-10. PubMed ID: 16914239
[TBL] [Abstract][Full Text] [Related]
26. A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5.
Xia L; Xian Y; Wang D; Chen Y; Huang X; Bi X; Yu H; Fu Z; Liu X; Li S; An Z; Luo W; Zhao Q; Xia N
Sci Rep; 2016 Jan; 6():19042. PubMed ID: 26750243
[TBL] [Abstract][Full Text] [Related]
27. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic.
Chen Y; Liu Y; Zhang G; Wang A; Dong Z; Qi Y; Wang J; Zhao B; Li N; Jiang M
Virus Res; 2016 Jul; 220():97-103. PubMed ID: 27107614
[TBL] [Abstract][Full Text] [Related]
28. Epitomics: IgG-epitome decoding of E6, E7 and L1 proteins from oncogenic human papillomavirus type 58.
Xu WX; Wang J; Tang HP; He YP; Zhu QX; Gupta SK; Gu SH; Huang Q; Ji CN; Liu LF; Li GL; Xu CJ; Xie Y
Sci Rep; 2016 Oct; 6():34686. PubMed ID: 27708433
[TBL] [Abstract][Full Text] [Related]
29. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies.
Christensen ND; Dillner J; Eklund C; Carter JJ; Wipf GC; Reed CA; Cladel NM; Galloway DA
Virology; 1996 Sep; 223(1):174-84. PubMed ID: 8806551
[TBL] [Abstract][Full Text] [Related]
30. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
[TBL] [Abstract][Full Text] [Related]
31. Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: an approach for a capsomere-based HPV vaccine.
Hassan SW; Waheed MT; Müller M; Clarke JL; Shinwari ZK; Lössl AG
Hum Vaccin Immunother; 2014; 10(10):2975-82. PubMed ID: 25483463
[TBL] [Abstract][Full Text] [Related]
32. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.
Wakabayashi MT; Da Silva DM; Potkul RK; Kast WM
Intervirology; 2002; 45(4-6):300-7. PubMed ID: 12566713
[TBL] [Abstract][Full Text] [Related]
33. [Prokaryotic expression of HPV 16 L1 gene and identification of its immune activity].
Hao DF; Ma ZH; Wang YP; Rexidan ; Zhang FC
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Jul; 21(4):428-31. PubMed ID: 15989783
[TBL] [Abstract][Full Text] [Related]
34. Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid.
Zhang C; Huang X; Chen S; Li Y; Li Y; Wang X; Tang J; Xia L; Lin Z; Luo W; Li T; Li S; Zhang J; Xia N; Zhao Q
Vaccine; 2018 Oct; 36(45):6761-6771. PubMed ID: 30287156
[TBL] [Abstract][Full Text] [Related]
35. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera.
Carter JJ; Wipf GC; Madeleine MM; Schwartz SM; Koutsky LA; Galloway DA
J Virol; 2006 May; 80(10):4664-72. PubMed ID: 16641259
[TBL] [Abstract][Full Text] [Related]
36. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.
Yang R; Wheeler CM; Chen X; Uematsu S; Takeda K; Akira S; Pastrana DV; Viscidi RP; Roden RB
J Virol; 2005 Jun; 79(11):6741-50. PubMed ID: 15890912
[TBL] [Abstract][Full Text] [Related]
37. [Preparation and identification of type specific and conformation dependent HPV16 L1 protein monoclonal antibody.].
Yan XF; Xu Y; Zheng J; Lai BC; Wang YL
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Dec; 25(12):1133-5. PubMed ID: 19961800
[TBL] [Abstract][Full Text] [Related]
38. Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33.
Roth SD; Sapp M; Streeck RE; Selinka HC
Virol J; 2006 Oct; 3():83. PubMed ID: 17014700
[TBL] [Abstract][Full Text] [Related]
39. Expression, purification, and antibody binding activity of human papillomavirus 16 L1 protein fused to maltose binding protein.
Cho HJ; Hahm MS; Kim MK; Han IK; Jung WW; Choi HG; Kim JA; Oh YK
Protein Pept Lett; 2007; 14(5):417-24. PubMed ID: 17584165
[TBL] [Abstract][Full Text] [Related]
40. Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.
Wang JW; Jagu S; Wu WH; Viscidi RP; Macgregor-Das A; Fogel JM; Kwak K; Daayana S; Kitchener H; Stern PL; Gravitt PE; Trimble CL; Roden RB
Clin Vaccine Immunol; 2015 Jul; 22(7):806-16. PubMed ID: 25972404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
